Death and Dying in Heart Failure With Normal Ejection Fraction

American Journal of Cardiology

Volumn 104, Issue 9, 2009, Pages 1311-1314

  Lim, Hoong Sern ^a   Beadle, Roger ^a   Frenneaux, Michael ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIGOXIN; IRBESARTAN; METOPROLOL; NEUROHORMONE; OMEGA 3 FATTY ACID; PERINDOPRIL; PLACEBO; ROSUVASTATIN; SPIRONOLACTONE;

CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DEATH; DEFIBRILLATOR; DISEASE SEVERITY; DYING; EDITORIAL; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART FAILURE WITH NORMAL EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SUDDEN DEATH; SURVIVAL RATE; SURVIVAL TIME;

HEART FAILURE; HUMANS; STROKE VOLUME;

EID: 71749118829     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.06.050     Document Type: Editorial

References (19)

1. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., Picard M.H., Roman M.J., Seward J., Shanewise J.S., Solomon S.D., Spencer K.T., Sutton M.S., and Stewart W.J. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18 (2005) 1440-1463
2. Paulus W.J., Tschope C., Sanderson J.E., Rusconi C., Flachskampf F.A., Rademakers F.E., Marino P., Smiseth O.A., De K.G., Leite-Moreira A.F., Borbely A., Edes I., Handoko M.L., Heymans S., Pezzali N., Pieske B., Dickstein K., Fraser A.G., and Brutsaert D.L. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28 (2007) 2539-2550
3. Vasan R.S., Benjamin E.J., and Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 26 (1995) 1565-1574
4. Bhatia R.S., Tu J.V., Lee D.S., Austin P.C., Fang J., Haouzi A., Gong Y., and Liu P.P. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355 (2006) 260-269
5. Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., and Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006) 251-259
6. Narang R., Cleland J.G., Erhardt L., Ball S.G., Coats A.J., Cowley A.J., Dargie H.J., Hall A.S., Hampton J.R., and Poole-Wilson P.A. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 17 (1996) 1390-1403
7. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
8. Kjekshus J., Apetrei E., Barrios V., Bohm M., Cleland J.G., Cornel J.H., Dunselman P., Fonseca C., Goudev A., Grande P., Gullestad L., Hjalmarson A., Hradec J., Janosi A., Kamensky G., Komajda M., Korewicki J., Kuusi T., Mach F., Mareev V., McMurray J.J., Ranjith N., Schaufelberger M., Vanhaecke J., van Veldhuisen D.J., Waagstein F., Wedel H., and Wikstrand J. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007) 2248-2261
9. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J., and Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
10. Tavazzi L., Maggioni A.P., Marchioli R., Barlera S., Franzosi M.G., Latini R., Lucci D., Nicolosi G.L., Porcu M., and Tognoni G. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008) 1223-1230
11. Mozaffarian D., Anker S.D., Anand I., Linker D.T., Sullivan M.D., Cleland J.G., Carson P.E., Maggioni A.P., Mann D.L., Pitt B., Poole-Wilson P.A., and Levy W.C. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation 116 (2007) 392-398
12. Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau R., Domanski M., Troutman C., Anderson J., Johnson G., McNulty S.E., Clapp-Channing N., Vidson-Ray L.D., Fraulo E.S., Fishbein D.P., Luceri R.M., and Ip J.H. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
13. Hobbs F.D., Roalfe A.K., Davis R.C., Davies M.K., and Hare R. Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). Eur Heart J 28 (2007) 1128-1134
14. Tribouilloy C., Rusinaru D., Mahjoub H., Souliere V., Levy F., Peltier M., Slama M., and Massy Z. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 29 (2008) 339-347
15. Ahmed A., Rich M.W., Fleg J.L., Zile M.R., Young J.B., Kitzman D.W., Love T.E., Aronow W.S., Adams Jr. K.F., and Gheorghiade M. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary Digitalis Investigation Group trial. Circulation 114 (2006) 397-403
16. Cleland J.G., Tendera M., Adamus J., Freemantle N., Polonski L., and Taylor J. The Perindopril in Elderly People With Chronic Heart Failure (PEP-CHF) study. Eur Heart J 27 (2006) 2338-2345
17. Massie B.M., Carson P.E., McMurray J.J., Komajda M., McKelvie R., Zile M.R., Anderson S., Donovan M., Iverson E., Staiger C., and Ptaszynska A. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359 (2008) 2456-2467
18. Yusuf S., Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., Olofsson B., and Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 362 (2003) 777-781
19. Ahmed A., Aronow W.S., and Fleg J.L. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. Am Heart J 151 (2006) 444-450